Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis - Takeaways - MDSpire

Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis

  • By

  • Yang Li

  • Jia Chen

  • Ting Sun

  • Yunfei Chen

  • Rongfeng Fu

  • Xiaofan Liu

  • Feng Xue

  • Wei Liu

  • Mankai Ju

  • Xinyue Dai

  • Huan Dong

  • Huiyuan Li

  • Wentian Wang

  • Ying Chi

  • Lei Zhang

  • March 18, 2024

  • 0 min

Share

  • 1

    Telomere length and epigenetic age acceleration are linked to the risk of various haematologic diseases, highlighting their importance in aging-related processes.

  • 2

    The study utilized Mendelian randomization to assess the causal relationship between genetically determined telomere length and haematologic disease risk.

  • 3

    Genetically increased telomere length was associated with higher odds ratios for multiple haematologic malignancies, including lymphoid leukaemia and Hodgkin lymphoma.

  • 4

    No significant association was found between DNA methylation GrimAge acceleration and haematologic diseases, while Hannum age acceleration showed a protective effect for chronic myeloid leukaemia.

  • 5

    PhenoAge acceleration was linked to increased risks of myeloid leukaemia and chronic lymphocytic leukaemia, indicating its potential role in haematologic disease risk.

Original Source(s)

Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis

  • by Yang Li, Jia Chen, Ting Sun, Yunfei Chen, Rongfeng Fu, Xiaofan Liu, Feng Xue, Wei Liu, Mankai Ju, Xinyue Dai, Huan Dong, Huiyuan Li, Wentian Wang, Ying Chi, Lei Zhang

  • March 18, 2024

Related Content

Multi-strategy feature selection and multi-model machine learning for prognostic prediction in primary gastric diffuse large B-cell lymphoma

Epstein-Barr virus associated diseases: Immune alterations and targeted approaches

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • by

  • February 9, 2026

  • 3 min